|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.71 USD | +3.18% |
|
-2.18% | +25.36% |
| 13/07 | Mizuho Raises Price Target on Nurix Therapeutics to $34 From $30, Keeps Outperform Rating | MT |
| 10/07 | Nurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says | MT |
| Market Cap | 238.49Cr 208.51Cr 192.35Cr 176.82Cr 335.03Cr 23TCr 340.75Cr 2.3TCr 901.02Cr 11TCr 895.63Cr 876Cr 39TCr | P/E 2026 * |
-8.29x | P/E 2027 * | -10x |
|---|---|---|---|---|---|
| Enterprise Value | 128.89Cr 112.69Cr 103.95Cr 96Cr 181.06Cr 12TCr 184.16Cr 1.24TCr 486.95Cr 6.06TCr 484.03Cr 473.43Cr 21TCr | EV / Sales 2026 * |
22.4x | EV / Sales 2027 * | 15.7x |
| Free-Float |
98.66% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nurix Therapeutics, Inc.
| 1 day | +3.09% | ||
| 1 week | -2.18% | ||
| Current month | -1.98% | ||
| 1 month | +39.55% | ||
| 3 months | +40.13% | ||
| 6 months | +26.09% | ||
| Current year | +25.36% |
| 1 week | 21.23 |  | 25.08 |
| 1 month | 16.5 | | 25.08 |
| Current year | 14.01 | | 25.08 |
| 1 year | 8.2 | | 25.08 |
| 3 years | 4.22 | | 29.56 |
| 5 years | 4.22 | | 37.42 |
| 10 years | 4.22 | | 52.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Arthur Sands
CEO | Chief Executive Officer | 64 | 18/09/2014 |
Hans van Houte
DFI | Director of Finance/CFO | 60 | 01/03/2016 |
Seema Rogers
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Judith Reinsdorf
BRD | Director/Board Member | 62 | 01/10/2021 |
Paul Silva
BRD | Director/Board Member | 60 | 01/10/2021 |
Arthur Sands
BRD | Director/Board Member | 64 | 18/09/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02/07 | Fiscal year | Compliance Officer | 33,024 | 0.0319% | ||
| 25/06 | Sell | Chief Technology Officer | -5,394 | 0.0052% | ||
| 25/06 | Fiscal year | Compliance Officer | 86,805 | 0.0839% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.18% | -2.18% | +95.72% | +141.18% | 238.49Cr | |
| -1.39% | -6.15% | +56.05% | +71.53% | 5.45TCr | |
| +3.13% | +11.16% | +67.30% | +94.35% | 5.59TCr | |
| -0.47% | -5.98% | +6.51% | +429.30% | 2.39TCr | |
| +1.77% | -1.56% | -16.79% | -14.12% | 2.29TCr | |
| +3.51% | +7.50% | +47.81% | -3.33% | 2TCr | |
| +1.94% | +0.21% | +39.31% | -29.41% | 1.75TCr | |
| +10.00% | -2.06% | +210.10% | +370.99% | 1.54TCr | |
| +7.69% | +4.38% | +56.51% | +712.88% | 1.52TCr | |
| -0.51% | -0.98% | +26.10% | +189.53% | 1.4TCr | |
| Average | +2.87% | -0.28% | +58.86% | +196.29% | 2.42TCr | |
| Weighted average by Cap. | +2.08% | +0.41% | +53.47% | +157.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.74Cr 5.02Cr 4.63Cr 4.26Cr 8.07Cr 552.79Cr 8.21Cr 55Cr 22Cr 270.19Cr 22Cr 21Cr 931.27Cr | 9.29Cr 8.12Cr 7.49Cr 6.88Cr 13Cr 893.54Cr 13Cr 89Cr 35Cr 436.74Cr 35Cr 34Cr 1.51TCr |
| Net income | -31Cr -27Cr -25Cr -23Cr -43Cr -2.95TCr -44Cr -294.84Cr -115.69Cr -1.44TCr -115Cr -112.48Cr -4.96TCr | -26Cr -23Cr -21Cr -19Cr -37Cr -2.53TCr -37Cr -252.71Cr -99Cr -1.23TCr -99Cr -96Cr -4.25TCr |
| Net Debt | -109.6Cr -96Cr -88Cr -81Cr -153.96Cr -11TCr -156.6Cr -1.06TCr -414.07Cr -5.15TCr -411.59Cr -402.57Cr -18TCr | -92Cr -81Cr -74Cr -68Cr -129.61Cr -8.88TCr -131.82Cr -888.36Cr -348.57Cr -4.34TCr -346.48Cr -338.89Cr -15TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | $23.77 | +3.44% | 5,09,283 |
| 14/26/14 | $22.98 | +1.19% | 15,72,819 |
| 13/26/13 | $22.71 | -1.52% | 15,50,880 |
| 10/26/10 | $23.06 | -6.60% | 15,54,089 |
| 09/26/09 | $24.69 | +1.56% | 13,44,872 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NRIX Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition